加利福尼亚州帕洛阿尔托，3月23日，2020年3月23日/ 3BL媒体/ - UC旧金山外科肿瘤科研实验室的旧金山董事David Donner博士解释了创新的新微流体技术在癌症研究中的好处。

关于HP的微流体

HP Inc.是根据MEMS行业报告中报告的MEMS行业报告所报告的基于设备收入的世界领导者，2019年。惠普在过去三十年中投资了数十亿美元的研发，以及资本设备to create the world’s largest digital printing company. All this provides the foundation to extend this technology into new domains. HP’s Specialty Printing Systems (SPS) and the Microfluidics Technology and Operations (MTO) teams have collaborated to bring HP’s first life science application in this space to market: The HP D300e BioPrinter with inkjet printing technology is enabling automated laboratory dispensing to “print” pharmaceutical samples instead of ink. The BioPrinter is being used by labs and pharmaceutical companies all over the world, including the Centers for Disease Control & Prevention (CDC) in the Antibiotic Resistance (AR) Lab Network, to perform antimicrobial susceptibility testing for health departments and hospitals nationwide. Learn more:http://www.hp.com/go/bioprint.。

关于HP Inc.

HP Inc.（纽约证券交易所）通过我们的个人系统，打印机和3D打印解决方案的产品和服务组合，我们的工程师体验惊讶。有关HP Inc.的更多信息可供选择www.hp.com.。

媒体联系人
Lacey Haines.
lacey.haines@hp.com.
http://press.ext.hp.com.